Abbott Laboratories (NYSE:ABT) Shares Acquired Rep. Byron Donalds

Representative Byron Donalds (R-Florida) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on April 14th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on March 20th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of GoDaddy (NYSE:GDDY) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Gartner (NYSE:IT) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Equifax (NYSE:EFX) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Tradeweb Markets (NASDAQ:TW) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Fiserv (NYSE:FI) on 3/20/2025.

Abbott Laboratories Trading Up 2.1 %

Shares of NYSE ABT traded up $2.76 during midday trading on Thursday, hitting $132.46. The stock had a trading volume of 4,509,270 shares, compared to its average volume of 6,050,480. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The company has a fifty day moving average price of $130.64 and a 200 day moving average price of $121.60. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $229.73 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 2.52 and a beta of 0.80.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.78%. Abbott Laboratories’s payout ratio is currently 30.85%.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Lisa D. Earnhardt sold 91,167 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the transaction, the executive vice president now owns 71,928 shares in the company, valued at approximately $9,625,404.96. This represents a 55.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 in the last quarter. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on ABT. Evercore ISI lifted their target price on shares of Abbott Laboratories to $136.00 and gave the stock a “buy” rating in a report on Thursday, January 2nd. StockNews.com downgraded Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. Barclays upped their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a research report on Thursday. Royal Bank of Canada lifted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Argus upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research report on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $142.59.

Institutional Trading of Abbott Laboratories

Institutional investors and hedge funds have recently modified their holdings of the company. Welch Group LLC boosted its position in shares of Abbott Laboratories by 5.3% during the fourth quarter. Welch Group LLC now owns 68,653 shares of the healthcare product maker’s stock worth $7,744,000 after purchasing an additional 3,479 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its position in Abbott Laboratories by 5.5% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,095,443 shares of the healthcare product maker’s stock valued at $133,691,000 after purchasing an additional 57,499 shares in the last quarter. Bath Savings Trust Co boosted its stake in shares of Abbott Laboratories by 3.7% in the 4th quarter. Bath Savings Trust Co now owns 166,132 shares of the healthcare product maker’s stock valued at $18,791,000 after purchasing an additional 5,881 shares in the last quarter. Bank Pictet & Cie Europe AG raised its position in shares of Abbott Laboratories by 1.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock worth $17,274,000 after acquiring an additional 2,774 shares during the last quarter. Finally, Pensionfund Sabic bought a new stake in Abbott Laboratories in the fourth quarter worth approximately $2,828,000. 75.18% of the stock is currently owned by institutional investors.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.